Literature DB >> 16584881

Exhaled nitric oxide as a diagnostic test for asthma in rhinitic patients with asthmatic symptoms.

Enrico Heffler1, Giuseppe Guida, Pietro Marsico, Roberta Bergia, Luisa Bommarito, Nicoletta Ferrero, Franco Nebiolo, Antonella De Stefani, Antonio Usai, Caterina Bucca, Giovanni Rolla.   

Abstract

BACKGROUND: Rhinitis is a major risk factor for asthma, so that evaluation of the lower airways is recommended in patients with rhinitis. Exhaled nitric oxide (FE(NO)) is considered a marker of airway inflammation and it has been found to be useful for the screening of patients with suspected diagnosis of asthma. Our aim was to assess the validity and accuracy of FE(NO) to identify patients with asthma in 48 non-smoking patients with persistent rhinitis and asthma-like symptoms.
METHODS: Asthma was diagnosed on the basis of 12% improvement in FEV1 after salbutamol or a methocholine PD(20)FEV1<800 microg. Prior to lung function FE(NO) was measured with the single exhalation method at 50 ml/s.
RESULTS: The geometric mean (95% confidence interval) FE(NO) was significantly higher in the 18/48 asthmatics than in the non-asthmatic patients (60 ppb, CI 95%: 50-89, versus 30 ppb, CI 95%: 28-45, P=0.001). Receiver operating characteristic (ROC) curve for the diagnosis of asthma indicated that FE(NO) is an acceptable discriminator between patients with and without asthma (area under the ROC curve=0.78). None of the asthmatic patients had FE(NO) values<25 ppb and all the patients with FE(NO)>100 ppb (n=5) were asthmatics. The sensitivity and specificity of FE(NO) for detecting asthma, using 36 ppb as cut-off point, were 78% and 60% and the positive and negative predictive values were 54% and 82%, respectively.
CONCLUSIONS: Measuring FE(NO) may be useful for the screening of rhinitic patients with asthma-like symptoms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16584881     DOI: 10.1016/j.rmed.2006.02.019

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  5 in total

1.  Diagnostic accuracy of exhaled nitric oxide in asthma: a meta-analysis of 4,691 participants.

Authors:  Zhenzhen Li; Wenzhe Qin; Lei Li; Qin Wu; Youjuan Wang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  Prevalence of asthma symptoms based on the European Community Respiratory Health Survey questionnaire and FENO in university students: gender differences in symptoms and FENO.

Authors:  Tamotsu Ishizuka; Shinichi Matsuzaki; Haruka Aoki; Masakiyo Yatomi; Yosuke Kamide; Takeshi Hisada; Takahiro Tsuburai; Kunio Dobashi; Kihachi Ohshima; Kazuo Akiyama; Masatomo Mori
Journal:  Allergy Asthma Clin Immunol       Date:  2011-09-19       Impact factor: 3.406

3.  Defining the normal range of fractional exhaled nitric oxide in children: one size does not fit all.

Authors:  Ran Wang; Stephen J Fowler; Stephen W Turner; Sarah Drake; Laura Healy; Lesley Lowe; Hannah Wardman; Miriam Bennett; Adnan Custovic; Angela Simpson; Clare S Murray
Journal:  ERJ Open Res       Date:  2022-09-12

4.  Peripheral blood MDSCs, IL-10 and IL-12 in children with asthma and their importance in asthma development.

Authors:  Yan-Li Zhang; Bin Luan; Xiu-Fang Wang; Jun-Ying Qiao; Li Song; Rui-Rui Lei; Wei-Xia Gao; Ying Liu
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

5.  Fractional Exhaled Nitric Oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC).

Authors:  Enrico Heffler; Giovanna Elisiana Carpagnano; Elisabetta Favero; Giuseppe Guida; Mauro Maniscalco; Andrea Motta; Giovanni Paoletti; Giovanni Rolla; Eugenio Baraldi; Vincenza Pezzella; Giorgio Piacentini; Stefano Nardini
Journal:  Multidiscip Respir Med       Date:  2020-02-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.